Alexion Pharmaceuticals is conducting a clinical trial called the PREVENT Study. The primary objective of the study is to assess the efficacy and safety of an investigational medicine as a potential treatment to prevent relapses in NMO and NMO Spectrum Disorder (NMOSD).
This is a randomized double blind study, where participants will receive investigational medication or placebo and neither the participant nor the study doctor or their staff will know who received the drug or placebo. In this study, 2 out of 3 participants will receive investigational medication and 1 out of 3 participants will receive placebo. The medication is given intravenously at the study doctor’s office or infusion center.
This study is not currently open for recruitment.
Participants may be eligible if they are at least 18 years old, have a positive test for the NMO-IgG antibody and have experienced 2 relapses in the past 12 months or 3 relapses in the last 24 months with at least 1 relapse in the last 12 months.
This is an “add-on study,” and patients may be able to continue taking their current NMO or NMOSD medications and receive the study medication.
There are known and unknown potential side effects, which will be discussed prior to enrollment and detailed in the informed consent.